Gossamer Bio Statistics
Total Valuation
Gossamer Bio has a market cap or net worth of $233.01 million. The enterprise value is $195.02 million.
| Market Cap | 233.01M |
| Enterprise Value | 195.02M |
Important Dates
The next estimated earnings date is Tuesday, August 6, 2024, after market close.
| Earnings Date | Aug 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Gossamer Bio has 226.22 million shares outstanding. The number of shares has increased by 137.94% in one year.
| Shares Outstanding | 226.22M |
| Shares Change (YoY) | +137.94% |
| Shares Change (QoQ) | +47.91% |
| Owned by Insiders (%) | 2.95% |
| Owned by Institutions (%) | 87.82% |
| Float | 189.89M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 8.72 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.13, with a Debt / Equity ratio of 7.72.
| Current Ratio | 7.13 |
| Quick Ratio | n/a |
| Debt / Equity | 7.72 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -12.13 |
Financial Efficiency
Return on equity (ROE) is -525.70% and return on invested capital (ROIC) is -76.26%.
| Return on Equity (ROE) | -525.70% |
| Return on Assets (ROA) | -62.70% |
| Return on Capital (ROIC) | -76.26% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.28M |
| Employee Count | 135 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -43.41% in the last 52 weeks. The beta is 1.93, so Gossamer Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.93 |
| 52-Week Price Change | -43.41% |
| 50-Day Moving Average | 0.79 |
| 200-Day Moving Average | 0.88 |
| Relative Strength Index (RSI) | 54.34 |
| Average Volume (20 Days) | 3,420,444 |
Short Selling Information
The latest short interest is 9.63 million, so 4.26% of the outstanding shares have been sold short.
| Short Interest | 9.63M |
| Short Previous Month | 9.98M |
| Short % of Shares Out | 4.26% |
| Short % of Float | 5.07% |
| Short Ratio (days to cover) | 2.88 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -177.78M |
| Pretax Income | -172.58M |
| Net Income | -172.58M |
| EBITDA | -155.21M |
| EBIT | -159.44M |
| Earnings Per Share (EPS) | -$1.00 |
Balance Sheet
The company has $244.39 million in cash and $206.41 million in debt, giving a net cash position of $37.99 million or $0.17 per share.
| Cash & Cash Equivalents | 244.39M |
| Total Debt | 206.41M |
| Net Cash | 37.99M |
| Net Cash Per Share | $0.17 |
| Equity (Book Value) | 26.72M |
| Book Value Per Share | 0.12 |
| Working Capital | 219.45M |
Cash Flow
| Operating Cash Flow | -158.47M |
| Capital Expenditures | n/a |
| Free Cash Flow | -158.47M |
| FCF Per Share | -$0.70 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Gossamer Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -137.94% |
| Shareholder Yield | -137.94% |
| Earnings Yield | -74.07% |
| FCF Yield | -68.01% |
Analyst Forecast
The average price target for Gossamer Bio is $9.20, which is 793.20% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.20 |
| Price Target Difference | 793.20% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |